Montecatini Edison, S. p. A. v. Rexall Drug & Chemical Co.

288 F. Supp. 486, 157 U.S.P.Q. (BNA) 309, 12 Fed. R. Serv. 2d 797, 1968 U.S. Dist. LEXIS 12307
CourtDistrict Court, D. Delaware
DecidedMarch 7, 1968
DocketCiv. A. No. 3343
StatusPublished
Cited by4 cases

This text of 288 F. Supp. 486 (Montecatini Edison, S. p. A. v. Rexall Drug & Chemical Co.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Montecatini Edison, S. p. A. v. Rexall Drug & Chemical Co., 288 F. Supp. 486, 157 U.S.P.Q. (BNA) 309, 12 Fed. R. Serv. 2d 797, 1968 U.S. Dist. LEXIS 12307 (D. Del. 1968).

Opinion

[488]*488MEMORANDUM OPINION

CALEB M. WRIGHT, Chief Judge.

On October 23, 1967 this Court ruled that the plaintiff answer defendant Rex-all’s Interrogatory 42 which reads as follows:

“Claim 1 of the patent in suit, 3 112 300, reads as follows:

‘A high molecular weight polypropylene consisting essentially of isotactic polypropylene made up of isotactic macromoleeules which are insoluble in boiling n-heptane and have substantially the type of stereo-regular structure illustrated in the model of a portion of an isotactic polypropylene maeromolecule, fully extended in a plane, as shown in FIGURE 2 of the accompanying drawing.’

“Claim 1 of U. S. Patent 3 112 301, issued 1963 November 26 and also assigned to plaintiff, reads as follows:

'As a new product, polypropylene consisting essentially of polypropylene which is insoluble in boiling ethyl ether, which is made up of macromolecules each of which shows the isotactic stereoregular structure, and which consists prevailingly but not essentially of isotactic macromolecules having substantially the isotactic structure and being insoluble in boiling n-heptane, the remainder of said macromolecules being soluble in boiling n-heptane.’
“(a) Precisely state where the dividing line is between the percentage of boiling n-heptane insoluble polypropylene having the isotactic structure which can be present in a polypropylene which plaintiff contends will infringe one of the above patents but not the other and identify by column and line where the basis is in each patent for the selected percentage.
“(b) What is the minimum percentage of boiling n-heptane insoluble polypropylene having the isotactic structure which plaintiff will contend must be present in a polypropylene to infringe Claim One of the patent in suit?
“(c) What is the maximum percentage of boiling n-heptane insoluble polypropylene having the isotaetic structure which plaintiff will contend can be present in a polypropylene product and such product consist ‘prevailingly but not essentially of isotactic’ polypropylene?
“(d) What is the maximum percentage of boiling n-heptane soluble propylene which can be present in a polypropylene product which plaintiff will contend to be an infringement of said Claim One of the patent in suit?”1

The plaintiff has filed a motion for reargument. The local rules of this Court governing the filing of such a motion have not been complied with inasmuch as the ^motion was filed out of time. Both the plaintiff and defendants, however, have filed extensive briefs. Because of the apparent importance of Interrogatory 42, in the interest of justice, and in order to facilitate the progress of what appears to be an unnecessarily long and complicated patent infringement suit, I have decided to overlook the technical noncompliance with the local rules and decide the plaintiff’s motion on its merits.

In support of the motion, plaintiff points to five areas in which the previous ruling was in error. The Court will consider these arguments seriatim.

1. “The construction of a claim is a question of law, not of fact, to which interrogatories are improperly directed.”

[489]*489This argument ignores the subtle, though significant, distinction between interrogatories which require a construction of a claim and those which merely ask that a party state his contentions. There is nothing impermissible in asking a party to state what he presently contends in an effort to ferret out or narrow the issues. In a complex patent case this may include asking a patentee what he contends the various terms of his patent mean. Hercules Powder Co. v. Rohm & Haas Co., 3 F.R. D. 328 (D.Del.1944). As whs observed in E. I. Du Pont De Nemours & Co. v. Byrnes, 1 F.R.D. 34 (S.D.N.Y.1939), a case which is analogous to the instant litigation: “The meaning of these terms will certainly be a subject of consideration and determination upon the trial and the evidence will be presented more skilfully and less wastefully and I perceive no substantial prejudice in requiring that such information be furnished in the preparation for the trial * * Again, the Court in Meese v. Eaton Manufacturing Co., 35 F.R.D. 162 (N. D.Ohio 1964) concluded that: “In patent cases, however, the Court can think of no one more qualified than the inventors to express opinion as to what constitutes theft of their inventiveness.”

It would seem that the logic of that decision would apply, a fortiori, to a situation where, as here, the plaintiff is merely being asked to state what he presently contends certain terms of the ’300 patent mean.

2. “The decision erroneously fails to recognize that patent claims are directed to a person skilled in the art, may properly use terms capable only of relative definition, and are to be finally construed only by the Court and only in light of the trial record as a whole.”

At the risk of being labeled an egotist and with some trepidation the Court will nonetheless state that it is not quite as untutored as this objection seems to assume. The point which this objection either fails to grasp, or is reluctant to come to grips with, is that defendants, who are presumably within the category of “person(s) skilled in the art,” contend that they do not understand the meaning of certain terms used in the- ’300 patent. Furthermore, though admittedly there may be terms that are capable of only relative definition, the terms of the ’300 patent which are the subject of Rexall’s Interrogatory 42 do not suggest that their meaning is being drawn from their relation to any more readily understood standard.2 Lastly, plaintiff’s answer to Rexall’s Interrogatory 42 will not usurp or in any way interfere with the obligation of the Court to make a determination as to the meaning and legal effect of the term, but rather would aid the Court in making a just and proper disposition of all of the issues in the case before it.

3. “The decision erroneously is intended to foreclose and if not vacated may in fact foreclose discovery of the facts relevant to a proper infringement determination.”

The Court “intended” to do nothing more than to properly decide the point of law which was before it. Discovery is a two-way street; while plaintiff should not be hampered in its discovery of matters relating to infringement, defendants are equally entitled to discovery relative to invalidity. The Court is unable to perceive how its decision on an interrogatory directed to the issue of invalidity can have any but the most tangential bearing upon the right to and scope of plaintiff’s discovery with [490]*490respect to the issue of infringement. As will appear later, plaintiff’s fears in this regard are wholly unfounded.

4. “The decision is posited on erroneous factual premises.”

In support of this contention, plaintiff urges that there is no controversy between the parties concerning the reference of “consisting essentially of” and further that “production documents from both Humble-Enjay and Rexall make it quite clear that these parties know full well

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Nestle Foods Corp. v. Aetna Casualty & Surety Co.
135 F.R.D. 101 (D. New Jersey, 1990)
Hercules Inc. v. Exxon Corp.
434 F. Supp. 136 (D. Delaware, 1977)
Babcock & Wilcox Co. v. Foster Wheeler Corp.
54 F.R.D. 474 (D. New Jersey, 1971)
United States v. Glaxo Group Limited
302 F. Supp. 1 (District of Columbia, 1969)

Cite This Page — Counsel Stack

Bluebook (online)
288 F. Supp. 486, 157 U.S.P.Q. (BNA) 309, 12 Fed. R. Serv. 2d 797, 1968 U.S. Dist. LEXIS 12307, Counsel Stack Legal Research, https://law.counselstack.com/opinion/montecatini-edison-s-p-a-v-rexall-drug-chemical-co-ded-1968.